Mixing Bupivacaine and Lidocaine for Peripheral Nerve Blocks in TKA
The FDA drug label explicitly states that "mixing or the prior or intercurrent use of any other local anesthetic with Bupivacaine Hydrochloride cannot be recommended because of insufficient data on the clinical use of such mixtures" 1. This is the definitive regulatory position that should guide practice.
The Core Safety Concern
The primary issue is lack of safety data, not a proven contraindication. The FDA's position reflects:
- Insufficient clinical data on the pharmacokinetics and toxicity profile of mixed local anesthetics
- Unpredictable drug interactions when combining agents with different cardiac toxicity profiles
- Bupivacaine's enhanced cardiotoxicity compared to lidocaine - at equal doses, bupivacaine has greater affinity and longer binding duration to cardiac sodium channels, making it more dangerous in overdose or inadvertent intravascular injection 2
What the Evidence Actually Shows
Despite the FDA warning, clinical practice commonly uses these mixtures, and research provides nuanced findings:
Dermatology Guidelines (2016)
The American Academy of Dermatology states that mixing bupivacaine and lidocaine for local infiltration and nerve blocks "is safe and effective," though they note insufficient data to determine whether combinations provide faster onset or longer duration compared to single agents 3. They conclude the decision "rests on the experience and comfort level of the clinician."
Recent Research Findings
For peripheral nerve blocks specifically:
A 2024 study comparing 0.5% bupivacaine alone versus 0.25% bupivacaine-1% lidocaine mixture for infraclavicular blocks found the mixture provided faster onset (20 vs 35 minutes) but significantly shorter duration of sensory block (18.7 vs 29.3 hours), motor block (18.9 vs 28.4 hours), and analgesia (24.3 vs 38.3 hours) 4
Another 2024 study of supraclavicular blocks showed the lidocaine-bupivacaine mixture achieved 95% complete conduction blockade at 40 minutes versus only 48% with bupivacaine alone, with intermediate duration of analgesia 5
A 2009 study demonstrated that mixtures resulted in higher plasma concentrations of lidocaine while reducing bupivacaine levels, raising the question of whether the safety benefit of lower bupivacaine is offset by significant lidocaine concentrations 6
Clinical Reality vs. Regulatory Guidance
The fundamental problem: You're trading faster onset for shorter duration, with unclear safety implications regarding total systemic local anesthetic load and potential for local anesthetic systemic toxicity (LAST).
For TKA Specifically
The 2008 Anaesthesia guidelines for TKA analgesia do not recommend mixing local anesthetics and make no mention of this practice as beneficial 7. Single-agent femoral nerve blocks with long-acting local anesthetics (bupivacaine, ropivacaine, levobupivacaine) are the evidence-based recommendation.
Practical Recommendation
Do not mix bupivacaine and lidocaine for peripheral nerve blocks in TKA. Instead:
Use single-agent long-acting local anesthetic (bupivacaine 0.25%, levobupivacaine 0.25%, or ropivacaine 0.2%) at appropriate volumes (0.2-0.5 mL/kg for peripheral blocks) 8
Accept the longer onset time (20-30 minutes) as the trade-off for prolonged analgesia (18-24+ hours)
If faster onset is critical, consider:
- Performing the block earlier in the preoperative period
- Using ultrasound guidance for more precise deposition
- Supplementing with systemic analgesics rather than mixing local anesthetics
If you encounter a mixture already prepared, recognize this represents off-label use with explicit FDA caution against the practice
Key Pitfall to Avoid
Do not assume that mixing provides "best of both worlds" - the research clearly shows you sacrifice duration for onset, and the safety profile remains inadequately characterized. The FDA warning exists precisely because we lack sufficient data on cumulative toxicity, drug interactions at the sodium channel level, and optimal dosing of combinations.